Filing Flows › Zomedica (ZOMDF) › Q2 2025
Zomedica (ZOMDF) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Zomedica (ZOMDF) reported revenue of $7.0M for the second quarter 2025 (Q2 2025), +14% from a year earlier and +7% from the quarter before. Operating margin was -115.4%, net loss $7.4M (106.2% of revenue).
Zomedica, Q2 2025: revenue $7.0M (+14% year over year), operating margin -115.4%, net loss $7.4M, operating cash flow −$5.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.0M | +7% | +14% |
| Operating profit | −$8.0M | — | — |
| Net earnings | −$7.4M | — | — |
| Operating cash flow | −$5.4M | — | — |
What changed
Revenue was $7.0M in Q2 2025, up 14% year over year and up 7% from the previous quarter. Consumables was the largest line at 76% of revenue. Consumables added $931K year over year (up 21%), 112% of the total change. Other declined 52%.
Gross margin was 67.0%, down 4.1 points from a year earlier. Operating costs exceeded revenue by $8.0M, an operating margin of -115.4%. Operating expenses fell 57% while revenue rose 14%. The fastest-growing cost line was Research & development (+25%). The quarter ended with a net loss of $7.4M, narrower than the previous quarter's $63.8M loss.
Operating cash flow was −$5.4M. Non-cash charges added back $1.9M of depreciation and amortization and $260K of share-based compensation. Capital expenditures of $137K exceeded it, leaving free cash flow of −$5.6M.
Questions
What was Zomedica's revenue in the second quarter 2025?
Zomedica (ZOMDF) reported revenue of $7.0M for the second quarter 2025 (Q2 2025), +14% from a year earlier and +7% from the quarter before.
Was Zomedica profitable in the second quarter 2025?
Operating loss was $8.0M (-115.4% of revenue) and net loss $7.4M.
Source: Zomedica 10-Q on SEC EDGAR.